HIV pre-exposure prophylaxis (PrEP) is a prevention strategy which includes the regular or event-driven use of antiretroviral medication to prevent HIV infection in adults. Several clinical trials ...

A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...

There is growing evidence that pre-exposure prophylaxis (PrEP) prevents HIV acquisition. However, in the United States, approximately only 4% of people who could benefit from PrEP are currently ...

Real-world data show DoxyPEP implementation among PrEP users significantly reduces the incidence of chlamydia and syphilis.

HIV pre-exposure prophylaxis (PrEP) is an effective and safe intervention for individuals with behaviors that are considered high risk for acquiring HIV infection. Despite the success of this ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

Kenya will this year begin rolling out a new long-acting injectable HIV prevention drug, Lenacapavir, positioning the country ...

Among individuals using HIV pre-exposure prophylaxis (HIV PrEP), doxycycline post-exposure prophylaxis (doxyPEP) was associated with a substantial decline in chlamydia and syphilis incidence.

MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (PFE) and Shionogi as shareholders, is pleased to ...

Kenya is preparing to introduce Lenacapavir, a long-acting HIV prevention injection that will be available next month.It is a ...

Kenya has taken a major step towards expanding HIV prevention options after the Ministry of Health formally recommended the registration of Lenacapavir, a long-acting antiretroviral medicine for HIV ...